MXCT: MaxCyte Inc. Price to Sales

Symbol and logo of brand MaxCyte Inc. (MXCT)

MaxCyte, Inc. (MXCT) holds a monopoly in electroporation, making the company indispensable for developers of gene therapies. The enterprise value-to-revenue multiple demonstrates the asset's market adaptation, where the current parameter equals 3.60. Stability is reinforced by robotic system production that eliminates defects. The ecosystem is completed by a licensing strategy that deeply integrates software and hardware into the business processes of B2B partners, blocking their transition to competitors.

MXCT (MaxCyte) P/S Multiple history from 07/04/2022 to 11/13/2026

Analytical breakdowns for MaxCyte, Inc (MXCT)

- market price and analyst price targets:
Stock Quotes maxcyte.com|MXCT - Analyst Consensus Forecast
- market capitalization information:
Market Value MaxCyte, Inc|MXCT - Enterprise Value
- shareholders' equity book value data:
Equity per Share MaxCyte|MXCT - Book Capitalization|Market Capitalization to Book Value maxcyte.com|MXCT - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio MaxCyte, Inc.|MXCT - Long-Term Debt to Capital|Short-Term Debt to Capital MaxCyte Inc|MXCT - Company Debts|Debt to Book Capitalization Ratio MaxCyte, Inc|MXCT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings MaxCyte|Immediate Liquidity maxcyte.com
- net income and valuation multiples indicators:
MXCT - Company Net Income|Projected Net Profit MaxCyte, Inc.|MXCT - Price to Earnings Ratio|Forward P/E Multiple MaxCyte Inc.|MXCT - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio MaxCyte, Inc|MXCT - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months MaxCyte|MXCT - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months maxcyte.com|MXCT - Earnings growth in current year|Expected net earnings per share growth next year MaxCyte, Inc.
- issuer revenue and sales details:
MXCT - Company Revenue|Company Revenue Forecast maxcyte.com|MXCT - Market Cap to Revenue|Price to Expected Revenue Ratio MaxCyte, Inc
Fundamental company analysis:maxcyte.com MXCT
Original product of MaxCyte, Inc

The P/S ratio is calculated as the ratio of market capitalization to annual revenue, determining the value of one dollar of sales in the eyes of investors. By analyzing the P/S multiple, one can assess the extent to which the market currently prices in the future success of the Flow Electroporation platform expansion and the scaling of B2B licenses for MaxCyte, Inc. (MXCT), separating speculative noise from real fundamental growth in business value.

Who MaxCyte, Inc. competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|TECH: P/S Multiple|BRKR - Price-to-Revenue Coefficient|AZTA (Azenta) - P/S Multiple|Market Cap to Revenue Varex Imaging Corp (VREX)|P/S Multiple SMLR|P/S Multiple Butterfly Corp (BFLY)|Price-to-Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Revenue Ratio|NNOX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTRX (Quanterix Corp.)|MASS: P/S Multiple|Price to Sales CapsoVision (CV)|Price-to-Revenue Ratio Rapid Micro Biosystems Inc.|SEER - Price-to-Revenue Multiple|Market Cap to Revenue HYPR (Hyperfine)|P/S Multiple FONAR Corp. (FONR)|P/S Multiple DXR (Daxor)|Price-to-Revenue Coefficient spectral-ai.com (MDAI)|VIVS - Price-to-Revenue Ratio|Price-to-Sales Ratio ACON|akoyabio.com (AKYA) - Price-to-Revenue Ratio|Market Cap to Revenue ThermoGenesis Holdings, Inc.|TLIS (Talis Biomedical Corp.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO